Life Science Investing Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology Kidney Week 2025
Life Science Investing Health Canada Grants Authorization for "LEQEMBI®" for the Treatment of Early Alzheimer's Disease
Life Science Investing Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
Life Science Investing Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
Life Science Investing LEQEMBI® IQLIK Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Life Science Investing LEQEMBI® IQLIK Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Life Science Investing Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Life Science Investing "LEQEMBI®" IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
Life Science Investing Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
Life Science Investing Biogen Receives European Commission Approval for ZURZUVAE® , the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Life Science Investing Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
